Fate Therapeutics Inc. Stock
€0.90
Your prediction
Fate Therapeutics Inc. Stock
Pros and Cons of Fate Therapeutics Inc. in the next few years
Pros
Cons
Performance of Fate Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc. | -2.220% | -19.352% | -26.343% | -65.576% | -41.239% | -95.500% | -97.792% |
| Krystal Biotech | 0.900% | 5.909% | 12.269% | 1.377% | 13.633% | 123.161% | - |
| Ardelyx Inc. | 1.410% | -2.024% | 10.187% | -19.190% | -1.531% | 232.223% | 8.236% |
| Evolus Inc | 6.960% | 6.140% | 11.009% | -60.458% | -42.381% | -19.333% | 129.951% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Fate Therapeutics, Inc. (US symbol FATE) paint a rather challenging picture amid the Biotechnology & Medical Research industry landscape. An examination of the company's recent performance reveals a combination of substantial operational struggles and notable potential for growth, accompanied by a significant cash burn. While their commitment to innovative research is commendable, the persistent negative net income and high expenditures raise concerns about their short-term viability.
Delving into the specifics, several pros and cons delineate the financial status of Fate Therapeutics.
Market Capitalization: Sitting at approximately $540.5 million, the company's market valuation isn’t inconsequential. Despite the struggles, a solid market cap can serve as a buffer for future fundraising or acquisition opportunities.
Comments
